AMA, Vaccine Integrity Project Release New Evidence Review for 2026-27 Respiratory Virus Immunizations
Independent review backs flu, COVID-19 and RSV vaccines ahead of the respiratory virus season, with no new safety concerns identified.
An Independent Look at the Evidence
The American Medical Association and the Vaccine Integrity Project announced the release of an independent evidence review to inform respiratory virus immunization recommendations for the 2026-27 season. The AMA partnered with the Vaccine Integrity Project to engage medical specialty societies and public health organizations in three areas: identifying key policy questions, reviewing emerging evidence, and communicating findings to clinicians and patients.
Recommendations by Patient Population
Four medical societies developed the population-specific recommendations:
- American Academy of Pediatrics — patients younger than 19
- American Academy of Family Physicians — patients 19 and older, and health care personnel
- American College of Obstetricians and Gynecologists — pregnancy
- Infectious Diseases Society of America — immunocompromised patients
JAMA Publishes Supporting Evidence Reviews
JAMA published evidence reviews covering all three respiratory pathogens — influenza, COVID-19, and RSV — along with a Perspective piece on the collaboration, giving physicians and other health professionals current evidence behind the immunization recommendations. The reviews found that immunizations against influenza, COVID-19, and RSV continue to provide meaningful protection against severe illness, hospitalization, and death, and researchers identified no new safety concerns in comparative studies.
New Resources for Clinicians and Patients
The AMA also launched a digital resource hub of immunization materials at SpreadTheFacts.org to help clinicians and patients access and share the recommendations. Clinicians can learn more directly from the organizations involved during their webinar on September 23 covering the evidence review process, key findings, and the latest respiratory virus immunization recommendations.
Sources: AMA press release; JAMA evidence reviews on influenza, COVID-19, and RSV; JAMA Perspective piece.






